Clinical and Genetic Analyzes of Age-related Macular Degeneration

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03614481

Acronym

COLDMLA

Enrollment

6000

Registered

2018-08-03

Start date

2005-11-30

Completion date

2024-11-30

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Brief summary

The purpose of this collection is to search for susceptibility genes for age-related macular degeneration (AMD) alone or in combination with environmental factors and to look for genes that modulate the AMD phenotype (particularly the response to treatment).

Interventions

GENETICSampling

Sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Inclusion criteria

* Age\> 55 years * Diagnosis of exudative or atrophic AMD in at least one eye * Patient informed of the objectives of the study and having freely signed the informed consent letter * Patient affiliated to a social security scheme

Exclusion criteria

* Other retinal or choroidal lesion in the studied eye * History of severe systemic disease that could potentially hinder patient adherence to the study protocol: mental disorder, cancer, recent stroke or heart failure less than 3 months old. * Known allergy to fluorescein, indocyanine green, iodine or ranibizumab

Design outcomes

Primary

Measure	Time frame	Description
Genotypic factors	6 months	Identification of genotypic factors associated with good or poor response to treatment in precisely phenotyped AMD patients.

Secondary

Measure	Time frame	Description
Predictive markers	6 months	Look for predictive markers of cure response among polymorphisms that are susceptibility factors for AMD
Vascular Endothelial Growth Factor	6 months	Look for predictors of treatment response among polymorphisms of other genes: Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor
Environmental factors	6 months	Look for predictive markers of treatment response among environmental factors
Predictive treatment response score	6 months	Create a predictive treatment response score that combines factors independently associated with the response to treatment in multivariate analysis
Circulating biological factors	6 months	Identification of circulating biological factors such as circulating fatty acids at risk of AMD or modulating the response to treatment.

Countries

France

Contacts

Primary ContactEric Soueid

eric.souied@chicreteil.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026